{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:26:55Z","timestamp":1779211615780,"version":"3.51.4"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T00:00:00Z","timestamp":1304899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Forum Allergy Rhinol"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>A previous study with azelastine nasal spray in patients with seasonal allergic rhinitis (SAR) demonstrated that increasing the azelastine concentration from 0.1% to 0.15% allowed for once\u2010daily dosing without increasing the incidence of adverse effects. This study evaluated the efficacy of azelastine 0.15% nasal spray administered once daily for treating symptoms of SAR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this 14\u2010day, randomized, double\u2010blind, placebo\u2010controlled study, patients with moderate\u2010to\u2010severe SAR were randomized to azelastine 0.15% (n = 251) or placebo (n = 255), both at a dosage of 2 sprays\/nostril once daily. The primary efficacy variable was change from baseline in the 12\u2010hour reflective Total Nasal Symptom Score (TNSS). Key secondary variables were change from baseline in 24\u2010hour instantaneous TNSS, to establish the dosing interval, and change from baseline in the Total Ocular Symptom Score (TOSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean improvement (3.57) and percentage improvement (19.3%) in 12\u2010hour reflective TNSS was significant (<jats:italic>p<\/jats:italic> &lt;  0.012) with azelastine 0.15% compared to placebo (2.14 and 11.4%, respectively). The mean improvement in 24\u2010hour instantaneous TNSS was also significant (<jats:italic>p<\/jats:italic> &lt;  0.001) for azelastine 0.15% compared to placebo, indicating efficacy with once\u2010daily dosing. The overall improvement and percentage improvement in TOSS was significant (<jats:italic>p<\/jats:italic> \u2264 0.012) with azelastine 0.15% (2.21 and 16.7%, respectively) compared to placebo (1.28 and 6.0%, respectively). The overall score for the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was significantly (<jats:italic>p<\/jats:italic> &lt; 0.001) improved from baseline in the azelastine group compared with the placebo group. Nasal discomfort (3.6%) and bitter taste (2.4%) were the most common adverse events. There were no reports of somnolence with azelastine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Azelastine 0.15% was effective and well tolerated with once\u2010daily dosing. Azelastine 0.15% nasal spray significantly improved a complex of eye symptoms compared to placebo. \u00a9 2011 ARS\u2010AAOA, LLC.<\/jats:p><\/jats:sec>","DOI":"10.1002\/alr.20065","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T17:35:57Z","timestamp":1304962557000},"page":"275-279","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of azelastine 0.15% nasal spray administered once daily in patients with allergy to Texas mountain cedar pollen"],"prefix":"10.1002","volume":"1","author":[{"given":"William C.","family":"Howland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niran J.","family":"Amar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Sacks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,9]]},"reference":[{"key":"e_1_2_7_2_2","volume-title":"Atlas of Allergic Diseases","author":"Fineman S","year":"2002"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)80040-1"},{"key":"e_1_2_7_4_2","first-page":"185","article-title":"Demographics and epidemiology of allergic and nonallergic rhinitis","volume":"22","author":"Settipane RA","year":"2001","journal-title":"Allergy Asthma Proc."},{"key":"e_1_2_7_5_2","volume-title":"Allergic and Nonallergic Rhinitis","author":"Druce HM.","year":"1998"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63155-9"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)80042-5"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90013-4"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90096-1"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1992.tb03085.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1993.tb02486.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2500\/105065897781751901"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90125-5"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90522-R"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)80196-5"},{"key":"e_1_2_7_16_2","first-page":"1143","article-title":"Effects of azelastine on the level of serum interleukin\u20104 and soluble CD23 antigen in the treatment of nasal allergy","volume":"48","author":"Ito H","year":"1998","journal-title":"Arzneimittelforschung."},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2009.30.3284"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1991.tb00807.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70380-5"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902890512"},{"key":"e_1_2_7_21_2","first-page":"331","article-title":"The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis","volume":"24","author":"DeWester J","year":"2003","journal-title":"Allergy Asthma Proc."},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60453-X"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S8088"}],"container-title":["International Forum of Allergy &amp; Rhinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Falr.20065","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alr.20065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T12:34:51Z","timestamp":1697027691000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/alr.20065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,9]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1002\/alr.20065"],"URL":"https:\/\/doi.org\/10.1002\/alr.20065","archive":["Portico"],"relation":{},"ISSN":["2042-6976","2042-6984"],"issn-type":[{"value":"2042-6976","type":"print"},{"value":"2042-6984","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,9]]}}}